Capital raised by Claris Biotherapeutics
2 Form D filings · first filed Feb 2025 · Jersey City, NJ
President & CEO
Signatory on Claris Biotherapeutics's Form D filings · $5.6M raised across 2
Clarke Atwell is on file as President & CEO at Claris Biotherapeutics in Jersey City, NJ. Claris Biotherapeutics has 2 Form D filings on record, $5.6M raised in total. Clarke Atwell appears as a signatory on the company's filings.
CSB-001 is a topical ocular biologic solution that harnesses the regenerative properties of recombinant human variant hepatocyte growth factor (dHGF). This product is specifically engineered to promote and expedite healing in the cornea, which is vital for restoring vision in patients suffering from corneal diseases.